VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH…
Read the full articleYou might also wanna read
AI accelerates search for cancer therapeutics in Korea
Artificial intelligence (AI) has helped SK Telecom and SK Biopharmaceuticals identify promising early compounds for a targeted cancer therap
AI Advances in Drug Discovery: From Data Integration to Dual-Action Cancer Drug Design
Featured content
drugtargetreview.com·5mo agoResearch on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy
Conditions : Breast Cancer Sponsors : Zhejiang Cancer Hospital Not yet recruiting
Whitehawk swoops in for five ADCs via development deal with China's Biocytogen
Biocytogen and Whitehawk Therapeutics are joining forces to develop bispecific antibody-drug conjugates using Biocytogen's discovery platfor
South Korea’s AimedBio Invests in Inocras, Partners on WGS for Cancer Trials
The companies hope to find patients likely to respond to AimedBio’s antibody-drug conjugates.
Avacta Therapeutics presents platform-validating data for faridoxorubicin in salivary gland cancer at BIO International Conference
Responses observed in patients with very low FAP expression with persistence of FAP expression observed despite tumor response
avacta.com·21d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.